SENJU PHARMACEUTICAL CO., LTD.
🇯🇵Japan
Clinical Trials
51
Active:3
Completed:46
Trial Phases
5 Phases
Phase 1:2
Phase 2:5
Phase 3:1
+2 more phases
Drug Approvals
7
NMPA:7
Drug Approvals
Bromfenac Sodium Eye Drops
- Product Name
- 普罗纳克
- Approval Number
- 国药准字HJ20150243
- Approval Date
- Jan 23, 2024
NMPA
Sodium Hyaluronate Eye Drops
- Product Name
- 玻璃酸钠滴眼液
- Approval Number
- 国药准字HJ20140024
- Approval Date
- Nov 24, 2023
NMPA
Pirenoxine Ophthalmic Solution
- Product Name
- 吡诺克辛滴眼液
- Approval Number
- 国药准字HJ20181134
- Approval Date
- Sep 20, 2022
NMPA
Sodium Hyaluronate Eye Drops
- Product Name
- 玻璃酸钠滴眼液
- Approval Number
- H20140024
- Approval Date
- Dec 21, 2018
NMPA
Clinical Trials
Distribution across different clinical trial phases (36 trials with phase data)• Click on a phase to view related trials
Not Applicable
27 (75.0%)Phase 2
5 (13.9%)Phase 1
2 (5.6%)Phase 3
1 (2.8%)Phase 4
1 (2.8%)Single Dose ADME Study of [14C]SJP-0008 in Healthy Male Subjects
- First Posted Date
- 2022-04-11
- Last Posted Date
- 2022-04-11
- Lead Sponsor
- Senju Pharmaceutical Co., Ltd.
- Target Recruit Count
- 6
- Registration Number
- NCT05320861
- Locations
- 🇬🇧
Quotient Sciences, Ruddington, Nottingham, United Kingdom
Safety, PK and Efficacy Study of SJP-0132 in Subjects With Dry Eye Disease
- First Posted Date
- 2019-10-25
- Last Posted Date
- 2023-04-20
- Lead Sponsor
- Senju Pharmaceutical Co., Ltd.
- Target Recruit Count
- 89
- Registration Number
- NCT04139122
- Locations
- 🇺🇸
Senju Investigational Site, Cypress, California, United States
A Study to Assess the Safety, Tolerability and Effectiveness of MT-0814 for the Treatment of Age-related Macular Degeneration
- First Posted Date
- 2019-03-11
- Last Posted Date
- 2021-04-20
- Lead Sponsor
- Senju Pharmaceutical Co., Ltd.
- Target Recruit Count
- 13
- Registration Number
- NCT03869684
- Locations
- 🇺🇸
Senju Investigational Site, Murray, Utah, United States
A Study to Assess the Safety and Effectiveness of SJP-0035 for the Treatment of Patients With Dry Eye Disease
Phase 3
Completed
- Conditions
- Dry Eye Syndromes
- Interventions
- Drug: SJP-0035 0.001%Drug: Placebo
- First Posted Date
- 2018-05-17
- Last Posted Date
- 2019-04-16
- Lead Sponsor
- Senju Pharmaceutical Co., Ltd.
- Target Recruit Count
- 329
- Registration Number
- NCT03527212
- Locations
- 🇺🇸
Arizona Eye Center, 1500 West Ray Road, Chandler, Arizona, United States
🇺🇸Walman Eye Center, 10615 West Thunderbird Boulevard, Suite D180, Sun City, Arizona, United States
🇺🇸SoCal Eye Physicians and Associates Surgery Center, 3300 E. South Street, Long Beach, California, United States
Safety and Efficacy of SJP-0035 Ophthalmic Solution in Patients With Moderate to Severe Corneal Epithelial Disorders
Phase 2
Completed
- Conditions
- Corneal Epithelial Disorders
- Interventions
- Drug: Low Dose SJP-0035 Ophthalmic SolutionDrug: High Dose SJP-0035 Ophthalmic SolutionDrug: Vehicle of SJP-0035 Ophthalmic solution
- First Posted Date
- 2016-10-11
- Last Posted Date
- 2021-04-13
- Lead Sponsor
- Senju Pharmaceutical Co., Ltd.
- Target Recruit Count
- 130
- Registration Number
- NCT02929823
- Locations
- 🇺🇸
Senju Investigational Site, Norfolk, Virginia, United States
- Prev
- 1
- 2
- Next
News
No news found